You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
據報百濟神州(06160.HK)在美啟動澤布替尼治療新冠重症患者二期臨床試驗
阿思達克 04-17 14:19
市傳百濟神州(06160.HK)正在美國針對其Brukinsa(澤布替尼)開展一項在重症COVID-19患者中的臨床試驗。據《北京日報》引述百濟神州有關負責人確認了該消息。

據了解,百濟神州已向美國FDA提交了一項二期隨機試驗申請,計劃招募42名美國患者,預計在兩至三個月內取得試驗結果。

有研究顯示,澤布替尼BTK抑制帶來的炎症減少可能有助於降低COVID-19誘導的呼吸窘迫嚴重程度,從而可能降低存在生命危險的COVID-19重症患者的死亡率和輔助通氣需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account